There was also a gradual decrease of total HER2 with increased concentrations of neratinib, which is consistent with a previously published report that neratinib induced HER2 ubiquitylation and endocytic degradation via its dissociation with HSP90 in HER2 positive breast cancer cells [25]. The gene discussed is ERBB2; the disease is breast carcinoma.